Equities research analysts forecast that Recro Pharma (NASDAQ:REPH) will announce ($0.68) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Recro Pharma’s earnings, with estimates ranging from ($0.76) to ($0.54). Recro Pharma reported earnings of ($0.42) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 61.9%. The company is expected to report its next earnings results on Thursday, May 10th.

According to Zacks, analysts expect that Recro Pharma will report full-year earnings of ($3.02) per share for the current year, with EPS estimates ranging from ($4.10) to ($2.43). For the next year, analysts anticipate that the firm will report earnings of ($1.36) per share, with EPS estimates ranging from ($1.70) to ($0.89). Zacks’ EPS averages are an average based on a survey of analysts that follow Recro Pharma.

How to Become a New Pot Stock Millionaire

Recro Pharma (NASDAQ:REPH) last released its quarterly earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.85) by $0.22. Recro Pharma had a negative return on equity of 75.97% and a negative net margin of 69.61%. The firm had revenue of $19.04 million for the quarter, compared to the consensus estimate of $12.88 million.

Several equities analysts have recently weighed in on REPH shares. Zacks Investment Research cut Recro Pharma from a “hold” rating to a “sell” rating in a report on Wednesday, January 10th. Oppenheimer started coverage on Recro Pharma in a report on Tuesday, February 13th. They issued an “outperform” rating and a $19.00 price objective for the company. UBS started coverage on Recro Pharma in a report on Tuesday, February 13th. They issued an “outperform” rating for the company. CIBC started coverage on Recro Pharma in a report on Wednesday, February 14th. They issued an “outperform” rating and a $19.00 price objective for the company. Finally, ValuEngine upgraded Recro Pharma from a “sell” rating to a “hold” rating in a report on Thursday, March 1st. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $14.21.

In related news, major shareholder Healthcare Master Fun Broadfin sold 200,000 shares of Recro Pharma stock in a transaction dated Tuesday, March 13th. The stock was sold at an average price of $10.07, for a total transaction of $2,014,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 20.90% of the company’s stock.

A number of institutional investors have recently bought and sold shares of REPH. Lyon Street Capital LLC bought a new position in Recro Pharma during the fourth quarter worth about $3,362,000. State Street Corp bought a new position in Recro Pharma during the second quarter worth about $1,047,000. Schwab Charles Investment Management Inc. boosted its holdings in shares of Recro Pharma by 166.5% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 81,269 shares of the specialty pharmaceutical company’s stock worth $752,000 after acquiring an additional 50,769 shares during the period. Alyeska Investment Group L.P. boosted its holdings in shares of Recro Pharma by 3.4% during the third quarter. Alyeska Investment Group L.P. now owns 906,398 shares of the specialty pharmaceutical company’s stock worth $8,139,000 after acquiring an additional 29,799 shares during the period. Finally, Wells Fargo & Company MN boosted its holdings in shares of Recro Pharma by 115.6% during the fourth quarter. Wells Fargo & Company MN now owns 52,848 shares of the specialty pharmaceutical company’s stock worth $489,000 after acquiring an additional 28,340 shares during the period. Institutional investors and hedge funds own 56.84% of the company’s stock.

Shares of REPH traded up $0.30 during midday trading on Wednesday, hitting $11.32. The stock had a trading volume of 57,286 shares, compared to its average volume of 203,455. The company has a market capitalization of $214.88, a price-to-earnings ratio of -5.68 and a beta of -0.75. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.75 and a quick ratio of 1.55. Recro Pharma has a twelve month low of $5.81 and a twelve month high of $12.23.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2018/04/16/zacks-brokerages-anticipate-recro-pharma-reph-will-announce-earnings-of-0-68-per-share.html.

About Recro Pharma

Recro Pharma, Inc, a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.

Get a free copy of the Zacks research report on Recro Pharma (REPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.